Over a century ago, uveitis, sclerokeratitis, pemphigus, and keratoconjunctivitis were treated with systemic administration of hypophyseal-derived adrenocorticotropic hormone. Although expanding research has effectively improved the use of corticosteroids locally, various side effects prevent patient compliance. Scientists are continuously developing different strategies and logical and dynamic approaches to enhance the acceptance of corticosteroid drug delivery. Objective: Over recent decades, the number of problems associated with using corticosteroids was overcome by changing the route of systemic drug delivery to ocular drug delivery. The recent development of lipid-based drug delivery has made it possible to enhance the bioavailability of corticosteroid ocular drug delivery. These novel methods may overcome the ocular barriers and side effects of conventional eye drops. Many of these formulations are presently undergoing clinical trials, and few are clinically effective. Result: This review presents an overview of corticosteroid-loaded cubosomal drug delivery as a non-invasive, nanoparticulate topical ocular delivery system. Conclusion: This novel formulation is easy to formulate, has a high residence time, sustains drug release, and enhances the bioavailability of corticosteroids. On this basis sheds light on the anatomy of the eye, various barriers to ocular drug delivery, various approaches for ocular drug delivery, mechanism of cubosomal absorption, polymers used, methods, and evaluation parameters for the development of cubosome